

> 流行病學 and risk factors (NEJM 2003;349:366)


# PROSTATE CANCER

流行病學 and risk factors (_NEJM_ 2003;349:366)

• Most common cancer in U.S. men; 2nd most common cause of cancer death in men

• Lifetime risk of prostate cancer dx ~16%; lifetime risk of dying of prostate cancer ~3%

• ↑ risk with ↑ age (rare if <45 y), in African Americans, ⊕ FHx, BRCA mutations

臨床表現

• Most prostate cancers (78%) are asymptomatic and localized at diagnosis

• Metastatic dis. sx primarily from bone mets: bone pain, spinal cord compression, cytopenias

Screening (_JAMA_ 2014;311:1143; _Lancet_ 2014;384:2027)

• **PSA:** 4 ng/mL cut point neither Se nor Sp; can ↑ with BPH, prostatitis, acute retention, after bx or TURP, and ejaculation (_no significant_ ↑ _after DRE, cystoscopy_); 15% of men >62 y with PSA <4 & 正常 DRE have bx-proven T1 cancer (_NEJM_ 2004;350:2239)

• Digital rectal exam no longer recommended due to limitations, no mortality benefit

• ACS rec: ≥50 y (or ≥45 y AA or ⊕ FHx) discuss PSA screening, informed decision making

• USPSTF (_JAMA_ 2018;319:1901) rec _against_ screening if asx (no ↓ in prostate ca-related mort.)

Diagnostic evaluation, staging, and 治療 (_NCCN Guidelines_ v4.2018)

• **Transrectal ultrasound** (TRUS) **guided biopsy** (6–12 cores)

• Multiparametric MRI (± endorectal coil): improves detection (_NEJM_ 2018;378:1767)

• **Gleason grade and grouping (histology**_): Gleason score_ = sum of Gleason grades (1 = best, 5 = worst) of 2 most prevalent patterns in bx; correlates with prognosis

![](https://i.imgur.com/MLxydx7.jpg)

\*In asx 病人 with life expectancy ≤5 y & very low-to-intermediate risk disease, no workup or Rx indicated until sx. _NEJM_ 2016;375:1415 & 2017;376:417 & 2018;378:2465 & 2018;379:2319; _JCO_ 2016;34:2182.

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>治療 of Metastatic Prostate Cancer</b> <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;378:645)</span></p></td></tr><tr><td><p><b>Androgen deprivation therapy (ADT)</b></p></td><td><p>Prostate ca requires androgen signaling for growth. ADT backbone of Rx.</p><p>Med: 1. Luteinizing hormone-releasing hormone (LHRH) agonist<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(eg, goserelin) ± 1<sup>st</sup>-gen anti-androgen (nilutamide, bicalutamide), <i>or</i></p><p>&nbsp;&nbsp;&nbsp;&nbsp;2. LHRH antagonist (degarelix)</p><p>Surg: Bilateral orchiectomy</p></td></tr><tr><td><p><b>Hormone- sensitive prostate cancer (HSPC)</b></p></td><td><p><b>Def:</b> ADT sensitive (ie, PSA ↓ with Rx): all prostate ca initially sensitive</p><p><b>Workup/testing:</b> PEx &amp; PSA q 3-6 mos; sx-guided imaging</p><p><b>Rx:</b> 1. ADT; <i>or</i><br>2. Docetaxel + ADT (↑ OS vs. ADT alone, espec. in high-volume dis.); <i>or</i> 3. ADT + abiraterone/pred (↑ OS vs. ADT alone)</p></td></tr><tr><td><p><b>Castration-resistant prostate cancer (CRPC)</b></p><p><i>Always continue ADT</i></p></td><td><p><b>Def:</b> All met. HSPC eventually becomes CRPC (ie, progression despite castration level of androgens on ADT), due to re-estab. of androgen signaling via other mech. ∴ more potent anti-androgens are active Rx.</p><p><b>Rx: New-gen. anti-androgens:</b> abiraterone (biosynth inhib.), enzalutamide (receptor blocker), &amp; apalutamide (receptor blocker) ↑ PFS &amp; OS</p><p><b>Chemo:</b> docetaxel &amp; cabazitaxel +pred/dex</p><p><b>Bone-active agents:</b> 1. denosumab or zoledronic acid ↓ skeletal-related events (SREs); 2. radium-223 used in bone-only dis, ↓ SREs &amp; ↑ OS</p><p><b>Misc:</b> <i>Homologous recombination-defic. tumors (BRCA1/2, ATM)</i>: olaparib; <i>MSI-H/Lynch synd.</i>: pembrolizumab; <i>Cancer vaccine</i>: Sipuleucel-T</p></td></tr></tbody></table>

_NEJM_ 2010;363:411 & 2013;368:138 & 2013;369:213 & 2014;371:424 & 2015;373:737 & 2015;373:1697 & 2017;377:338 & 352; 2018;378:1408; 2019;381:13; _Lancet_ 2016;387:1163; _JCO_ 2017; 35:2189.

Prognosis

• PSA level, Gleason grade and age are predictors of metastatic disease

• In surgically treated 病人, 5-y relapse-free survival >90% if disease confined to organ, ~75% if extension through capsule, and ~40% if seminal vesicle invasion

• Metastatic disease: median survival ~44–57 mo (_NEJM_ 2015;373:737)
